A carregar...

Biosimilar Insulin and Costs: What Can We Expect?

The costs for insulin treatment are high, and the steady increase in the number of patients with diabetes on insulin presents a true challenge to health care systems. Therefore, all measures to lower these costs are welcomed by patients, physicians, and health care providers. The market introduction...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Diabetes Sci Technol
Autor principal: Heinemann, Lutz
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4773960/
https://ncbi.nlm.nih.gov/pubmed/26350722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296815605337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!